SCHEMBL970590

SCHEMBL970590

Nc1ccc(-c2nnc(S)s2)cc1N

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 4/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SNCA P37840 1/20 0.40
KCNH2 Q12809 2/20 0.39
MGAM O43451 4/20 0.38
GAA P10253 4/20 0.38
SI P14410 4/20 0.38
MGAM2 Q2M2H8 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
NOTUM Q6P988 1/20 0.38
QPCT Q16769 2/20 0.36
QPCTL Q9NXS2 2/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14557099 0.80 KDM4E (0.43) KDM4EALDH1A1MAPTL3MBTL1SNCA
SCHEMBL11025151 0.76 KDM4E (0.49) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL14557095 0.75 SNCA (0.37) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL969945 0.75 PIK3CA (0.40) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL9179420 0.74 SNCA (0.75) MAPTSNCAHSD17B1
SCHEMBL8042809 0.74 ALDH1A1 (0.64) MEN1KMT2ATDP1KDM4EALDH1A1
SCHEMBL969364 0.73 PTPN11 (0.47) KDM4EALDH1A1MAPTSNCASMN1; SMN2
SCHEMBL969071 0.73 NPC1 (0.47) MEN1KMT2AKDM4EALDH1A1KCNH2
SCHEMBL8042087 0.71 PIM1 (0.47) KDM4EALDH1A1MAPTL3MBTL1SNCA
SCHEMBL8047389 0.71 CA1 (0.49) KDM4EALDH1A1SNCAMGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7871982-B2 Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient MEIJI SEIKA KAISHA, LTD. (JP) 2011-01-18 US disclosed
US-20090156512-A1 potent activity against resistant pneumococci MEIJI SEIKA KAISHA, LTD. (JP) 2009-06-18 US disclosed
EP-1970377-A1 LINCOMYCIN DERIVATIVE AND ANTIBACTERIAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MEIJI SEIKA KAISHA LTD. (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156512-A1 potent activity against resistant pneumococci H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 MEN1 299/4885KMT2A 2133/4885TDP1 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.